Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Serum Albumin Is Incrementally Associated With Increased Mortality Across Varying Levels of Kidney Function Publisher Pubmed



Browntortorici AR1 ; Naderi N1, 2 ; Tang Y1 ; Park C1 ; You AS1 ; Norris KC3 ; Obi Y1 ; Streja E1 ; Kalantarzadeh K1, 3 ; Rhee CM1, 4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Harold Simmons Center for Kidney Disease Research and Epidemiology, Division of Nephrology and Hypertension, University of California Irvine School of Medicine, Orange, United States
  2. 2. Nephrology Research Center, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, United States
  4. 4. Tibor Rubin Veterans Affairs Medical Center, Long Beach, United States

Source: Nutrition Published:2020


Abstract

Objectives: Serum albumin (sAlb) may be a strong predictor of longevity in the general population and in chronic kidney disease. This study aimed to determine the relationship between sAlb concentrations and mortality risk independent of kidney function. Methods: This was a retrospective cohort study of 31 274 adults from the 1999–2010 National Health and Nutrition Examination Survey. The estimated glomerular filtration rate (eGFR) was examined as both a confounder and modifier of the association of sAlb with mortality risk. We examined the association of sAlb (categorized as <3.8, 3.8 to <4.0, 4.0 to <4.2, 4.2 to <4.4, 4.4 to <4.6, 4.6 to <4.8, and ≥4.8 g/dL) with mortality using Cox models. Subsequently, we conducted spline analyses to estimate the association of sAlb with all-cause mortality across varying eGFR levels. Results: In unadjusted analyses, participants with incrementally lower sAlb concentrations of <4.6 g/dL had an increasingly higher mortality risk compared with those with sAlb levels ranging from 4.6 to <4.8 g/dL (reference), whereas those with higher sAlb levels of ≥4.8 g/dL had a lower mortality risk (hazard ratios [95% confidence interval]: 3.88 [3.26–4.62], 3.59 [3.01–4.27], 2.79 [2.37–3.29], 2.10 [1.79–2.48], 1.72 [1.45–2.03], and 0.71 [0.55–0.92] for sAlb concentrations of <3.8, 3.8 to <4.0, 4.0 to <4.2, 4.2 to <4.4, 4.4 to <4.6, and ≥4.8 g/dL, respectively). Adjusted analyses showed similar findings, although the association of higher sAlb levels of ≥4.8 g/dL with better survival was attenuated to the null. Spline analyses showed that participants with sAlb levels of <4.6 g/dL had higher mortality across all concentrations of eGFR, ranging from 30 to 120 mL/min/1.73 m2 (reference: sAlb ≥ 4.6 g/dL). Conclusions: Among a nationally representative U.S. cohort, a graded association was observed between lower sAlb concentrations and higher death risk, which was robust across varying levels of kidney function. © 2020